Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the appendix, download the attached PDF.

CARETEQ - Q3-FY23 ACTIVITIES REPORT & APPENDIX 4C (ASX:CTQ)

Number of new Sofihub contracts won jumps 55% over previous quarter to 34 with a further 18 paid trials currently running Eight of the 34 contracts won and 11 of the 18 tr...read more

Chimeric Therapeutics - New CLTX CAR technology patent protection in India & Israel (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only ASX-listed clinical stage cell therapy company, is pleased to announce that the Indian Patent Offi...read more

Chimeric Therapeutics - Phase 1B brain cancer clinical trial approved for initiation (ASX:CHM)

New Chimeric Phase 1B clinical trial of CHM 1101 receives approval from ethics review board The Phase 1B trial will involve participation of multiple clinical sites Chi...read more

CARETEQ - ShareCafe Webinar Presentation (ASX:CTQ)

To view the presentation, please download the attached PDF.

Careteq forms Strategic JV (ASX:CTQ)

Highlights: Careteq to merge its Ward MM business with Mederev in a JV to be called Embedded Health Solutions and create one of Australia’s largest aged care medication manageme...read more

Chimeric Therapeutics - CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation (ASX:CHM)

-- Acceptance of CHM 1101 abstract for presentation at premier oncology meeting, Annual Meeting of the American Society of Clinical Oncology (ASCO) -- Abstract will highlight the clinical trial des...read more

Carbonxt Group - Prepayment to expedite development of Kentucky facility (ASX:CG1)

US$500,000 prepayment confirmed to advance development of state-of-the-art activated carbon plant in Kentucky, USA Funding will facilitate the purchase of longer lead-time...read more

Chimeric Therapeutics - Positive pre-IND meeting with FDA for Phase 1 CAR T study (ASX:CHM)

-- Chimeric has received positive feedback and guidance from the US Food and Drug Administration (FDA) regarding its proposed Phase 1 clinical trial in gastrointestinal and neuroendocrine tumors wit...read more

Chimeric Therapeutics - Fourth dose cohort initiated in CHM 1101 Phase 1 trial (ASX:CHM)

-- The 1st patient in the 4th dose cohort of the CHM 1101 (CLTX CAR T cell) clinical trial at the City of Hope has received dosing at City of Hope Cancer Center -- Dosing in the 4th dose cohort wil...read more

Chimeric Therapeutics - Appendix 4D and Half Year Report (ASX:CHM)

For more information, download the attached PDF.

Carbonxt Group - HY23 Results Announcement (ASX:CG1)

OPERATIONS OVERVIEW Half year revenue of $8.9 million, down 10% on HY22, primarily due to maintenance for the installation of new equipment at the Arden Hills and Black Birch manufact...read more

Carbonxt Group - Half Yearly Report and Accounts (ASX:CG1)

To view the Half Yearly Report and Accounts, download the attached PDF.

Careteq - Appendix 4D & Half Year Results (ASX:CTQ)

Highlights: -- Interim revenue increased by 36% to $2.6m as net loss improved materially by ~$1.5m -- Contract wins in US and Australia, expanded suite of offerings, lower costs and contribution...read more

Careteq - Half Year Results Presentation (ASX:CTQ)

To view the presentation, download the attached PDF.

Viewing: 61 - 75 of 200 Previous | Next